GSK3β expression and activation in A375 BRAF-V600E mutant melanoma cells were assessed prior to BRAFi treatment, in BRAFi-sensitive cells and after developing BRAFi resistance at RNA and protein levels. Here, GSK3B is linked to melanoma.